Stockholm Stock Exchange | Mid Cap
Xvivo Perfusion
+25.84%
Latest
+25.84%
3 months
Pareto SecuritiesSEB EquitiesSEBDanske BankDNBDanske Bank MarketsDNB MarketsCarnegieBryan Garnier

Price Targets For Xvivo Perfusion

AnalystPrice TargetDateUpside
Pareto Securities560 SEKOct -24
+25.84%
SEB Equities610 SEKOct -24
SEB600 SEKJul -24
Danske Bank560 SEKJul -24
DNB468 SEKApr -24
Danske Bank Markets405 SEKApr -24
DNB Markets418 SEKJan -24
Carnegie350 SEKJan -24
Bryan Garnier340 SEKNov -23

About The Company

XVIVO is a medical technology company firmly rooted within medical science with more than 20 years of experience in the transplantation area.
Xvivo Perfusion